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Bladder cancer is the second most common tumor of the urogenital tract. Urothelial 
carcinoma is the most frequent histologic type, being unique among epithelial carcinomas in 
its divergent pathways of tumorigenesis. Surgery continues to have a predominant role in 
the management of urothelial bladder cancer (Kaufman et al., 2009). However, the debate 
about the best treatment approach for T1G3 and muscle invasive tumors continually 
challenges all urologic surgeons and oncologists. This debate involves several aspects. First, 
a significant number of T1G3 tumors recurs and progresses rapidly after transurethral 
resection and BCG treatment (Wiesner et al., 2005). Second, half of patients with invasive 
tumors have a dismal outcome despite an effective treatment by radical cystectomy 
(Sternberg et al., 2007). Third, the extension of lymphadenectomy remains an issue of 
controversy, although clinical evidence suggests that an extended lymph node dissection 
may not only provide prognostic information, but also a significant therapeutic benefit for 
both lymph node-positive and lymph node-negative patients undergoing radical cystectomy 
(May et al., 2011). In muscle invasive bladder cancer, the presence of tumor foci in lymph 
nodes is an early event in progression, and the lymphatic vessels within or in the proximity 
to the primary tumor serve as the primary conduits for tumor dissemination (Youssef et al., 
2011). Fourth, although urothelial bladder cancer is a chemo-sensitive tumor (Kaufman et 
al., 2000; von der Maase et al., 2000), adjuvant systemic chemotherapy does not reveal 
benefits (Walz et al., 2008), and neoadjuvant chemotherapy is not yet accepted as the best 
approach in invasive bladder cancer (Clark, 2009). Therefore, in order to solve the 
aforementioned problems, it is crucial to improve the knowledge about tumor 
microenvironment, regulation of cancer metabolism and neovascularization. 
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Blood and lymphatic neovascularization are essential for tumor progression and metastasis, 
by promoting oxygenation and fluid drainage, and establishing potential routes of 
dissemination (Adams and Alitalo, 2007). Therefore, the inhibition of tumor-induced 
neovascularization represents a powerful option for target therapy, in order to restrain the 
most efficient pathway of cancer spread.   
2. Angiogenesis and lymphangiogenesis: Molecular regulation of vasculature 
development 
During embryogenesis, the formation of the blood vascular system initiates by 
vasculogenesis: haemangioblasts proliferate, migrate and differentiate into endothelial cells, 
which in turn will organize a primitive vascular plexus. In parallel, angiogenesis promotes 
the remodeling and expansion of the primary capillary network, originating a hierarchical 
structure of different sized vessels that will mature into functional capillaries, veins and 
arteries (Risau, 1997). The lymphatic vascular system develops latter, when a group of blood 
endothelial cells differentiates into a lymphatic endothelium that subsequently sprouts to 
form the primary lymph sacs. By lymphangiogenesis, the lymphatic endothelial cells from 
the lymph sacs will further sprout, originating the peripheral lymphatic system (Sabin, 1902, 
as cited by Oliver & Detmar, 2002). 
During postnatal life, blood and lymphatic vascular systems are, normally, in a quiescent 
state. Physiological angiogenesis and/or lymphangiogenesis occur to maintain or restore the 
integrity of tissues, namely during wound healing and the ovarian cycle. Conversely, the 
neovascularization machinery may be activated in pathological processes such as cancer and 
inflammatory diseases (reviewed in Lohela et al., 2009).  
Similarly to physiological neovascularization, tumor-induced angiogenesis and/or 
lymphangiogenesis occur to satisfy the metabolic demands of a new tissue ― the 
malignant tissue. Therefore, the molecular factors involved in the formation of the 
vascular systems during embryogenesis are newly recruited by the growing tumor 
(Papetti & Herman, 2002). 
2.1 From angiogenesis to lymphangiogenesis in the embryo 
The proliferation, sprouting and migration of endothelial cells during vasculogenesis and 
angiogenesis is mainly guided by the vascular endothelial growth factor (VEGF) signaling 
through VEGF receptor-2 (VEGFR-2) (Risau, 1997). 
VEGF (or VEGF-A), initially termed as vascular permeability factor (VPF) (Senger et al., 
1983), is a specific mitogen and pro-survival factor for blood endothelial cells, also 
stimulating vascular permeability. It binds and activates two tyrosine kinase receptors 
primarily found on the blood endothelium: VEGFR-1 (or Flt-1, fms-like tyrosine kinase 1) 
and VEGFR-2 (or KDR/Flk-1, human kinase insert domain receptor/mouse foetal liver 
kinase 1) (reviewed in Carmeliet, 2005). Interaction of VEGF with VEGFR-1 negatively 
regulates vasculogenesis and angiogenesis during early embryogenesis (Fong et al., 1999). 
On the contrary, VEGFR-2 is the earliest marker for endothelial cell development: mouse 
embryos lacking VEGFR-2 die at embryonic day 8.5-9.5 due to no development of blood 
vessels as well as very low hematopoiesis (Shalaby et al., 1995). Regarding the ligand, 
even heterozygote mice for Vegf deficiency die at embryonic day 11-12: blood islands, 
endothelial cells and vessel-like tubes fail to develop (Carmeliet et al., 1996; Ferrara et al., 
1996). 
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In humans, five weeks after fertilization, certain blood endothelial cells become responsive 
to lymphatic inducing-signals. The lymphatic vessel endothelial hyaluronan receptor-1 
(LYVE-1), a CD44 homologous transmembrane protein, is the first marker of lymphatic 
endothelial commitment.  Initially, it is evenly expressed by the blood endothelium of the 
cardinal vein, which causes the blood endothelium to acquire the ability to differentiate in 
lymphatic endothelium (Banerji et al., 1999). The polarized expression of the prospero 
related homeobox gene-1 (Prox-1) transcription factor in a subpopulation of blood 
endothelial cells determines the establishment of the lymphatic identity and initiates the 
formation of the lymphatic vascular system. In mice, Prox-1 expressing cells are first 
observed at embryonic day 10 in the jugular vein (Wigle & Oliver, 1999). Prox1 deletion 
leads to a complete absence of the lymphatic vasculature (Wigle et al., 2002). The expression 
of the transcription factor Sox18 [SRY (sex determining region Y) box 18] acts as a molecular 
switch to induce differentiation of lymphatic endothelial cells: it activates Prox-1 
transcription by binding to its proximal promoter. Sox18-null embryos show a complete 
blockade of lymphatic endothelial cell differentiation (François et al., 2008). Later, the 
sprouting, migration and survival of the newly formed lymphatic endothelial cells depends 
on the expression of VEGF-C by the mesenchymal cells surrounding the cardinal veins 
(Karkkainen et al., 2004) (Fig. 1).  
VEGF-C, like VEGF, is a member of the VEGF family of growth factors and a mitogen for 
lymphatic endothelial cells. VEGF-D is also a pro-lymphangiogenic factor, although its 
deletion does not affect the development of the primitive lymphatic vessels (Baldwin et al. 
2001). Conversely, in Vegfc-/- mice, Prox-1 positive cells appear in the cardinal veins, but fail 
to migrate and proliferate to form primary lymph sacs (Karkkainen et al., 2004). VEGF-C 
and VEGF-D interact with VEGFR-3 (of Flt-4, fms-like tyrosine kinase 4). Their affinity to 
VEGFR-3 is increased by proteolytic cleavage; the fully processed forms can also bind to 
VEGFR-2 (reviewed in Lohela et al., 2009). 
VEGFR-3 is widely expressed at the early stages of embryonic blood vasculature, becoming 
virtually restricted to lymphatic endothelium in the later stages of embryonic development, 
(after the lymphatic commitment mediated by Prox-1 expression), and during adult life 
(Kaipainen et al., 1995). In mice, inhibition of VEGFR-3 expression at embryonic day 15 
induces regression of the developing lymphatic vasculature by apoptosis of lymphatic 
endothelial cells (Makinen et al., 2001). 
The subsequent development of the lymphatic vasculature involves the separation of the 
blood and lymphatic vascular systems, the maturation of lymphatic vessels and the 
formation of secondary lymphoid organs. The molecular regulation of these processes 
involves the coordinated expression of distinct genes from those involved in the early 
events of lymphangiogenesis (reviewed in Alitalo et al., 2005) (Fig. 1). Moreover, several 
other growth factors, namely cyclooxygenase-2 (COX-2) fibroblast growth factor-2 (FGF-
2), hepatocyte growth factor (HGF), insulin-like growth factors (IGFs) and platelet-
derived growth factor-B (PDGF-B) have been shown to induce lymphangiogenesis and/or 
angiogenesis in experimental models (reviewed in Cao, 2005). These are mainly protein 
tyrosine kinases, which play central roles in signal transduction networks and regulation 
of cell behavior. In the lymphatic endothelium, these tyrosine kinases are collectively 
involved in processes such as the maintenance of existing lymphatic vessels, growth and 








Fig. 1. Model for the development of mouse lymphatic vasculature (E- embryonic day; Syk- 
protein-tyrosine kinase SYK; Slp76- SH2 domain-containing leucocyte protein, 76-kDa; 
Ang2- angiopoietin 2; Foxc2- Forkhead Box C2) (adapted by permission from © 2005 Nature 
Publishing Group. Originally published in Nature. 438: 946-953) 
2.2 Promotion of angiogenesis and lymphangiogenesis in the malignancy context 
The major cause of cancer mortality is the metastatic spread of tumor cells that can occur via 
multiple routes, including blood and lymphatic vasculatures. For metastasis to occur, 
selected clones of malignant cells must be able to invade the newly formed vessels and 
disseminate. Induction of angiogenesis and/or lymphangiogenesis is, therefore, one of the 
first steps of the metastatic cascade (Alitalo & Carmeliet, 2002; Tobler & Detmar, 2006). 
During the pre-vascular phase, the malignant tumor remains small (up to 1 or 2 mm3); the 
preexistent surrounding blood vessels ensure the supply of oxygen and nutrients necessary 
for its survival. However, the expansion of the tumor mass is angiogenesis-dependent. As a 
compensatory response to hypoxia, proangiogenic factors such as VEGF are released by the 
malignant cells and infiltrating immune cells, namely monocytes. As a result, angiogenesis 
occurs and the tumor acquires its own blood supply. Neoplastic growth is thus promoted, as 
well as the potential for invasion and haematogenic metastasis (Kerbel, 2000). 
Vegf is upregulated in hypoxia via the oxygen sensor hypoxia-inducible factor (HIF)-1 (Pugh 
& Ratcliffe, 2003). Another recently described VEGF activation mechanism is the induction of 
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the transcriptional coactivator peroxisoma proliferator-activated receptor-gamma coactivator-
1 (PGC-1) in response to the lack of nutrients and oxygen (Arany et al., 2008). Additionally, 
VEGF gene expression can be upregulated by oncogene signaling, several growth factors, 
inflammatory cytokines and hormones (reviewed in Ferrara, 2004). Tumor cells secrete VEGF 
mainly in a paracrine manner, although it can also act in an autocrine manner to promote a 
protective/survival effect to endothelial cells, among other cell types (Brusselmans et al., 2005). 
The mechanisms underlying tumor lymphangiogenesis are not clearly defined. Inflammation 
seems to promote lymphatic neovascularization: inflammatory cells that infiltrate in the 
growing tumor produce lymphangiogenic growth factors. Another lymphangiogenesis trigger 
mechanism may be the high interstitial pressure generated inside the tumors due to the 
excessive production of interstitial fluid (reviewed in Cao, 2005). On the other hand, the 
extracellular matrix is of central importance for the generation of new lymphatic vessels as a 
response to the pathological stimulus. Integrins, a superfamily of cell adhesion molecules, are 
able to influence cell migration: integrin 91 is a target gene for Prox1, and its direct binding 
to VEGF-C and VEGF-D stimulates cell migration (reviewed in Wiig, 2010). 
VEGF-C and VEGF-D, via signaling through VEGFR-3, appear to be essential for tumor-
associated lymphangiogenesis, leading to lymphatic vessel invasion, lymph node 
involvement and distant metastasis (reviewed in Achen & Stacker, 2008). Moreover, VEGF 
interaction with VEGFR-2 may also promote lymphatic neovascularization, namely inside 
the regional draining lymph nodes, even before lymph node metastasis occurrence. This 
probably corresponds to a pathophysiologic strategy of “soil” preparation by the primary 
tumor to ensure the success of its future dissemination (Hirakawa et al., 2005). In fact, 
sentinel lymph node metastasis is the first step in the spreading of many cancer types. 
Preexisting blood and lymphatic vessels in the vicinity of the malignant mass may 
contribute to tumor spread. However, de novo formed vessels by tumor-induced 
angiogenesis and lymphangiogenesis seem to be the preferential routes for dissemination 
(reviewed in Cao, 2005). This is a consequence of the ultra-structure of the tumor-associated 
blood and lymphatic vessels. 
2.3 Ultra-structure of tumor-associated blood and lymphatic vessels 
Blood vessels present in malignant tissues show remarkable differences with vessels present 
in normal tissues. Tumor blood vessels are highly disorganized: they are tortuous, 
excessively branched and dilated. The basement membrane and the muscular coverage are 
incomplete or absent. The endothelial cells, abnormal in shape, overlap and are projected 
into the lumen rather than organizing a pavement layer below the basement membrane. 
Blood vessel invasion is facilitated by this aberrant structure, but the extravasation rate is 
high, and blood flow is variable. As a result, interstitial tumor hypertension occurs, and 
delivery of therapeutic agents into tumors is compromised (Jain & Carmeliet, 2001; 
reviewed in Cao, 2005). The intratumoral edema is pernicious to malignant cells; therefore, 
homeostasis needs to be re-established. The formation of a tumoral lymphatic vasculature 
could potentially resolve this problem. 
The key function of lymphatic vessels is to collect the excessive amount of interstitial fluid 
back to the blood circulation for immune surveillance in lymph nodes. Unlike normal blood 
capillaries, lymphatic capillaries have a discontinuous or fenestrated basement membrane and 
are not ensheathed by pericytes or smooth muscle cells; the endothelial cells are arranged in a 
slightly overlapping pattern and lack tight interendothelial junctions. Specialized anchoring 
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filaments of elastic fibers connect the endothelial cells to the extracellular matrix, which causes 
the vessels to dilate rather than to collapse when hydrostatic pressure rises (Alitalo et al., 2005; 
Tobler & Detmar, 2006). This structure facilitates the collection of interstitial fluid and is ideal 
for malignant cells’ entry into the lymphatic flow. 
A highly debated question is whether there are functional lymphatic vessels inside tumors 
(reviewed in Alitalo & Carmeliet, 2002; reviewed in Detmar & Hirakawa, 2002). On one 
hand, the elevated interstitial pressure generated by the proliferation of the malignant cells 
and by the high extravasion rate compromises the infiltration of new lymphatic vessels in 
the tumor stroma. Although intratumoral lymphangiogenesis may occur, the newly formed 
vessels are compressed and nonfunctional (Jain & Fenton, 2002). To compensate the lack of 
an intratumoral draining mechanism, the peritumoral lymphatic vessels enlarge due to an 
excess of pro-lymphangiogenic factors in that area. Therefore, in this model, the peritumoral 
lymphatic vessels passively collect interstitial fluid and, eventually, malignant cells 
(Carmeliet & Jain, 2000) (Fig. 2, A). However, some studies have demonstrated a 
relationship between the existence of functional intratumoral lymphatics, with cycling 
lymphatic endothelial cells and tumor emboli, and lymph node involvement (reviewed in 
Da et al., 2008). Additionally, peritumoral lymphangiogenesis occurs, and the new vessels 
actively contribute to metastatic spread (Padera et al., 2002) (Fig. 2, B). Probably, there are 
some organ-specific determinants that influence the occurrence of peritumoral and/or 
intratumoral lymphangiogenesis, as well as the function of the newly formed vessels. 
2.4 Lymphovascular invasion and metastasis   
Tumor metastasis involves a coordinated series of complex events that include promotion of 
angiogenesis and lymphangiogenesis, detachment of malignant cells from the primary 
tumor, microinvasion of the surrounding stroma, blood and/or lymphatic vessel invasion, 
survival of the malignant cells in the blood and/or lymphatic flow, and extravasion and 
growth in secondary sites. Because the large lymphatic vessels reenter the blood vascular 
system, malignant cells spread via the lymphatic system to the regional lymph nodes and, 
from this point, to distant organs (Alitalo & Carmeliet, 2002; Tobler & Detmar, 2006) (Fig. 3). 
Follow-up data have shown that 80% of the tumors, mainly those of epithelial origin, 
disseminate through the lymphatic vasculature; the remaining 20% use the blood circulation 
to colonize secondary organs (reviewed in Saharinen et al., 2004; reviewed in Wilting et al., 
2005). 
The blood vessels are not the best route for the success of malignant dissemination. 
Although their disorganized structure may contribute to the intravasion of malignant cells 
or emboli, in the bloodstream these cells experience serum toxicity, high shear stresses and 
mechanical deformation. Consequently, the viability of the tumor cells is seriously 
compromised (reviewed in Swartz, 2001). Conversely, the success rate of lymphogenous 
spread is high. As previously referred, the structure and function of the lymphatic 
capillaries facilitates intravasion of tumor cells or emboli. On the other hand, the 
composition of the lymph is similar to interstitial fluid, which provides an optimal medium 
for the survival of malignant cells. In collecting lymphatic vessels, muscle fibers assure 
lymph propulsion, that flows slowly, and valves prevent its backflow. Lymph nodes are 
areas of flow stagnation that represent ideal “incubators” for malignant cells’ growth. Some 
cells exit the lymph node through the efferent channels or high endothelial venules.  
Other cells may remain mechanically entrapped for long periods of time, originating 
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Fig. 2. (A) Traditional model of tumor metastasis via lymphatic and blood vessels. (B) Active 
lymphangiogenesis model of tumor metastasis (reprinted by permission from © 2002 




Fig. 3. Pathways of dissemination of malignant cells (reprinted by permission from © 2008 
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micrometastases (Swartz, 2001; Van Trapen & Pepper, 2002). Martens and colleagues 
described the expression of a gene signature of scavenger and lectin-like receptors in the 
lymph node sinus, which are known mediators of tumour cell adhesion and, therefore, can 
contribute to selective metastasis in an organ-specific context (Martens et al., 2006). Probably, 
tumor-cell-specific characteristics, microenvironmental factors and crosstalk between tumor 
and host cells have a pivotal role in determining survival and growth of micrometastasis. 
Moreover, lymph node lymphangiogenesis may provide an additional mechanism to facilitate 
further metastatic spread throughout the lymphatic system (Ji, 2009). The occurrence of 
lymphangiogenesis prior to arrival of tumor cells indicates that signals derived from the 
primary tumor are transported to the draining lymph nodes (Hirakawa et al., 2005). 
Different tumors metastasize preferentially to different organs, suggesting that tumor 
spread is a guided process. It has been reported that malignant cells may use chemokine 
receptor ligand interactions to guide the colonization of target organs (reviewed in 
Saharinen et al., 2004; reviewed in Achen & Stacker, 2008). Chemokines are a family of 
chemoattractant cytokines that bind to G protein-coupled receptors expressed on target 
cells, namely malignant cells (Laurence, 2006). For instance, breast cancer cells, that 
normally choose regional lymph nodes, bone marrow, lung and liver as their first sites of 
destination, overexpress CCR7 (chemokine, CC motif, receptor 7) and CXCR4 (chemokine, 
CXC motif, receptor 4). Their ligands, SLC/CCL2 (secondary lymphoid chemokine / CC-
type chemokine ligand 21) and SDF-1 CXCL12/ (stromal cell-derived factor 1 / chemokine, 
CXC motif, ligand 12) are expressed at high levels by isolated lymphatic endothelial cells 
and lymphatic endothelium from vessels present in the preferred sites of metastasis (Muller 
et al., 2001). This guides chemoattraction and migration of tumor cells, and characterizes 
lymphatic vessel invasion as an active event. 
3. Angiogenesis, lymphangiogenesis and lymphovascular invasion in 
urothelial bladder cancer  
The metastatic profile of urothelial bladder carcinoma implies, as in most malignant tumors, 
the dissemination of tumor cells through the lymphatic vasculature, and the colonization of 
regional lymph nodes is an early event in progression. Smith & Whitmore reported the 
involvement of the internal iliac and obturator groups of lymph nodes in about 74% of patients 
who underwent radical cystectomy; the external iliac nodes were involved in 65% of the 
patients, and the common iliac nodes were involved in 20% of the cases (Smith & Whitmore, 
1981). As already referred, controversy exists regarding the optimal extent of 
lymphadenectomy and the number of lymph nodes to be retrieved at radical cystectomy. An 
extended pelvic lymph node dissection (encompassing the external iliac vessels, the obturator 
fossa, the lateral and medial aspects of the internal iliac vessels, and at least the distal half of 
the common iliac vessels together with its bifurcation) has been suggested as potentially 
curative in patients with metastasis or micrometastasis to a few nodes (Karl et al., 2009; Abol-
Enein et al., 2011). Wright and colleagues observed that an increased number of lymph nodes 
removed at the time of radical cystectomy associates with improved survival in patients with 
lymph node-positive bladder cancer (Wright et al., 2008). The recommendation from the 
Bladder Cancer Collaboration Group is that ten to fourteen lymph nodes should be removed 
at the time of radical cystectomy (Herr et al., 2004). The concept of lymph node density (the 
number of positive lymph nodes divided by the total number of lymph nodes) was introduced 
by Stein and colleagues and helps to select lymph node-positive patients after radical 
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cystectomy for adjuvant treatment (Stein et al., 2003). However, the lymph node density 
threshold is a debatable question (Gilbert, 2008). In large series, the median number of total 
lymph nodes removed was nine, with high lymph node density (25%), which can lead to 
misleading N0 staging (Wright et al., 2008). Therefore, in this subgroup of patients (lymph 
nodes removed ≤ 9 and N0), another prognostic factor is needed to better select patients for 
adjuvant treatment. Moreover, according to Malmström, extending the boundaries of surgery 
will not drastically improve survival. The focus should be on exploring biomarkers that 
predict extravesical dissemination and improving on the systemic treatment concept 
(Malmström, 2011). In this line of investigation, angiogenesis, lymphangiogenesis and 
lymphovascular invasion occurrence have been implicated in bladder cancer progression, 
invasion and metastasis, and represent potential targets for guided therapy. 
Several studies reported a significant association between VEGF overexpression ― both in 
tumor tissue (Crew et al., 1997; O’Brien et al., 1995) and urine (Crew et al., 1999; Jeon et al., 
2001) ―, high blood vessel density (Goddard et al., 2003; Santos et al., 2003) and the 
occurrence of recurrence and progression in patients with non-muscle invasive bladder 
cancer. In this group of patients, it has been observed that angiotensin II type 1 receptor 
(AT1R) expression associates with high blood vessel density and is related to early 
intravesical recurrence (Shirotake et al., 2011). AT1R supports tumor-associated macrophage 
infiltration, which results in enhanced tissue VEGF protein levels (Egami et al., 2009). These 
results suggest that AT1R is involved in bladder tumor angiogenesis and may become a new 
molecular target and a prognostic factor for urothelial bladder cancer patients  
In the subset of invasive urothelial bladder cancer, most studies also reported the 
association between angiogenesis occurrence and unfavorable prognosis. High blood vessel 
density was identified as an independent prognostic factor by several authors (Bochner et 
al., 1995; Chaudhary et al., 1999; Dickinson et al., 1994; Jaeger et al., 1995). Moreover, 
overexpression of VEGF associates with high blood vessel density (Sato et al., 1998; Yang et 
al., 2004). Analysis of serum levels of VEGF has demonstrated its optimal sensitivity and 
specificity for predicting metastatic disease (Bernardini et al., 2001). Inoue and colleagues 
reported the importance of measuring blood vessel density and VEGF immunoexpression in 
identifying patients with invasive tumors who are at high risk of recurrence and 
development of metastasis after radical cystectomy and neoadjuvant systemic 
chemotherapy. The author highlighted the role of VEGF as a cell survival factor, not only by 
protecting the malignant cells in situations of hypoxia, but also during the occurrence of 
chemotherapy-induced apoptosis (Inoue et al., 2000). 
Beyond VEGF signaling, other angiogenesis-related molecules have been implicated in 
bladder cancer recurrence, progression and metastasis, namely several proangiogenic 
factors ― matrix metalloproteinases, fibroblast growth factors, platelet derived-growth 
factors, cyclooxygenases, integrins, angiopoietins, Notch signaling ― and several 
antiangiogenic factors ― thrombospondin-1, angiostatin-endostatin, platelet factor-4 
(Chikazawa et al., 2008; Durkan et al., 2001; Grossfeld et al., 1997;  Patel et al., 2006; reviewed 
in Pinto et al., 2010; Shariat et al., 2010). 
The relevance of lymphangiogenesis in bladder cancer setting has gained recent attention. A 
few articles suggest that lymphangiogenesis occurrence, detected using specific lymphatic 
markers, is associated with poor prognosis (Fernández et al., 2008; Ma et al., 2010; Miyata et 
al., 2006; Zhou et al., 2011; Zu et al., 2006). VEGF-C, VEGF-D and VEGFR-3 are 
overexpressed in bladder cancer and promote tumor-induced lymphangiogenesis. This 
correlates with tumor upstaging and lymph node involvement, and results in a worse 
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prognosis (Afonso et al., 2009; Miyata et al., 2006; Suzuki et al., 2005; Herrmann et al., 2007; 
Zhou et al., 2011; Zu et al., 2006). Interestingly, VEGF-C overexpression also associates with 
angiogenic events, probably by interaction of the fully processed form with VEGFR-2 
(Afonso et al., 2009; Miyata et al., 2006). On the other hand, tumor associated macrophages 
play an important role in promoting lymphangiogenesis by producing VEGF-C and VEGF-
D, mainly in peritumoral areas (Schoppmann et al., 2002). The blockade of VEGF-C/D with 
a soluble VEGF receptor-3 markedly inhibited lymphangiogenesis and lymphatic metastasis 
in an orthotopic urinary bladder cancer model. In addition, the depletion of tumor 
associated macrophages exerted similar effects (Yang et al. 2011). 
Lymphovascular invasion has been identified as an independent prognostic factor for bladder 
cancer patients in several studies (Cho et al., 2009; Leissner et al., 2003; Lotan et al., 2005; Quek 
et al., 2005). In patients with newly diagnosed T1 urothelial bladder cancer, lymphovascular 
invasion in transurethral resection of bladder tumor specimens predicts disease progression 
and metastasis (Cho et al., 2009). Lotan and colleagues observed that blood and lymphatic 
vessel invasion (accessed by Haematoxylin-eosin stain) is an independent predictor of 
recurrence and low overall survival in patients who undergo radical cystectomy for invasive 
urothelial bladder cancer and are lymph node negative. They emphasized that these patients 
represent a high risk group that may benefit from neoadjuvant or adjuvant treatments. 
However, in this study, the mean number of lymph nodes removed per patient at the time of 
radical cystectomy was 20,1±10,2 (Lotan et al., 2005). 
The prognostic impact of lymphovascular invasion in patients with lymph node-negative 
urothelial bladder cancer treated by radical cystectomy has been recently validated in large 
multicentre trials (Bolenz et al., 2010; Shariat et al, 2010). May and colleagues emphasized that, 
besides the importance of performing extended lymphadenectomies, the information resulting 
from an assessment of lymphovascular invasion is critical for stratification of risk groups and 
identification of patients who might benefit from adjuvant treatments (May, 2011). Algaba 
underlined that, in this field, it would be necessary to reach a consensus on strict diagnostic 
criteria as soon as possible, to be able to incorporate this prognostic factor in clinical practice 
(Algaba, 2006). Leissner and colleagues endorsed that blood and lymphatic vessel invasion 
should be commented on separately in the pathology report (Leissner et al., 2003). 
Afonso and colleagues reported the prognostic contribution of molecular markers of blood 
vessels (like CD31) (Fig. 4, A) and lymphatic vessels (like D2-40) (Fig. 4, B) to accurately 
assess the occurrence of blood and/or lymphatic vessel invasion. The use of endothelial 
markers is encouraged because immunohistochemistry antibodies are significantly more 
sensitive in detecting invasive events than the standard Haematoxylin-eosin staining 
method and, additionally, facilitate the discrimination between blood and lymphatic vessel 
invasion. This is particularly important in identifying isolated malignant cells invading 
lymphatic vessels, because their viability is more probable in the lymphatic flow than in the 
blood circulation. Conversely, emboli of malignant cells are better suited to survive in the 
bloodstream, and are more easily identified, even by the traditional Haematoxylin-eosin 
staining method. This advocates the use of lymphatic markers for purposes of counting 
invaded lymphatic vessels. In this study, blood vessel invasion by malignant emboli 
assessed by CD31 staining (Fig. 5, A), and lymphatic vessel invasion by isolated malignant 
cells assessed by D2-40 staining (Fig. 5, B) significantly affected patients’ prognosis; blood 
vessel invasion remained as an independent prognostic factor (Afonso et al., 2009). When 
included in a model of bladder cancer aggressiveness, these parameters contributed to a 
clear separation between low and high aggressiveness groups (Afonso et al., 2011).  
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Fig. 4. Intratumoral blood vessels highlighted by CD31 (A), and intratumoral lymphatic 
vessels highlighted by D2-40 (B), in invasive urothelial bladder carcinoma. Evidence of 
internal negative control in A (D2-40 negative blood vessel ) (original magnification x100) 
(reprinted by permission from © 2009 John Wiley & Sons, Inc. Originally published in 
Histopathol. 55: 514-524) 
Both peritumoral and intratumoral lymphatic vessels seem to be functional for urothelial 
cells’ dissemination. Some articles reported the existence of intratumoral lymphatic 
vessels in bladder tumors, and their possible participation in metastatic events. No 
intratumoral edema has been observed, which is consistent with the occurrence of 
efficient lymphatic neovascularization (Afonso et al., 2009; Fernández et al., 2008; Ma et 
al., 2010; Miyata et al. 2006). Lymphatic vessel invasion occurrence correlates with high 
lymphatic vessel density values, mainly in the intratumoral areas. Although most of the 
invaded lymphatic vessels were distorted and collapsed, single malignant cells were 
significantly observed in the well-preserved intratumoral lymphatic vessels (Fig. 5, B). 
Moreover, the absence of intratumoral edema is a surrogate marker of an efficient 
lymphatic flow (Afonso et al., 2009). 
 
  
Fig. 5. Intratumoral blood vessel highlighted by CD31 invaded by a small malignant 
embolus (A), and intratumoral lymphatic vessel highlighted by D2-40 invaded by an 
isolated malignant cell (B), in invasive urothelial bladder carcinoma (original magnification 
x100) (reprinted by permission from © 2009 John Wiley & Sons, Inc. Originally published in 
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4. Angiogenesis and Lymphangiogenesis as therapeutic targets in urothelial 
bladder cancer  
Our current understanding of the importance of tumor-induced angiogenesis and 
lymphangiogenesis for the occurrence of haematogenous and lymphogenous metastasis 
suggests that, by blocking the activity of key molecules involved in these processes, it 
should be possible to suppress the onset of metastasis following diagnosis of cancer and its 
subsequent therapy. Moreover, prophylactic suppression of metastasis would be useful for 
patients who are at risk of recurrence (Thiele & Sleeman, 2006). Therefore, clinical trials 
evaluating novel agents and combinations including chemotherapeutic drugs, as well as 
targeted inhibitors, are desperately needed (Iyer et al., 2010). 
Two types of neovascularization inhibitors have been described. The direct inhibitors refer 
to compounds that function directly on endothelial cells by blocking a common pathway of 
vessel growth. Indirect inhibitors are molecules that neutralize the functions of angiogenic 
and lymphangiogenic growth factors; due to their mode of action, these are preferred over 
the direct inhibitors (Cao, 2005; Folkman, 2003). The main strategies that have been tested 
focus on modulating the signaling of VEGF family of growth factors and receptors, and are 
based on the use of monoclonal antibodies or soluble versions of receptors to neutralize the 
ligand-receptor interaction, and the inhibition of the kinase activity of the receptors (Achen 
et al., 2006; Thiele & Sleeman, 2006).  
In 2004, the U.S. Food and Drug Administration (FDA) has approved bevacizumab 
(Avastin®), a humanized monoclonal antibody that binds to VEGF-A, as the first drug 
developed solely for antiangiogenesis anticancer use in humans. Antiangiogenic drugs are 
presently approved in a wide number of tumor types, namely in breast, colorectal, lung, 
liver, glioblastoma and kidney cancer. Other compounds are currently in preclinical 
development, with many of them now entering the clinic and/or achieving approval 
(reviewed in Boere et al., 2010; reviewed in Cook & Figg, 2010; reviewed in Pinto et al., 
2010).  
In anticancer therapy, an angiogenesis inhibitor may prevent the growth of new blood 
vessels. This should decrease the delivery of oxygen and nutrients – the “starving therapy” – 
which are indispensable elements for the support of uncontrolled cell division and tumor 
expansion. Angiogenesis inhibitors are predicted to be cytostatic, stabilizing tumors and 
perhaps preventing metastasis, rather than being curative (Zhi-chao & Jie, 2008). Therefore, 
there is the need to administrate this type of therapy for long periods of time. As a 
consequence, problems with bleeding, blood clotting, heart function and depletion of the 
immune system are common (Cohen et al., 2007). Nevertheless, inhibition of circulating 
VEGF reduces vascular permeability and thus tumoral interstitial pressure, permitting 
easier penetration of the tumor by conventional chemotherapeutic targets (Ferrara, 2005). 
A second concern of anti-angiogenesis therapy is the approach to objectify the response to 
anti-angiogenic drugs. Chan and colleagues found that targeted contrast enhanced micro-
ultrasound imaging enables investigators to detect and monitor vascular changes in 
orthotopic bladder tumors. Therefore, this technique may be useful for direct, noninvasive 
and in vivo evaluation of angiogenesis inhibitors (Chan et al., 2011). Lassau and colleagues 
demonstrated that dynamic ultrasound can be used to quantify dynamic changes in tumor 
vascularity as early as three days after the administration of the anti-angiogenic drug. These 
changes may be potential surrogate measures of the effectiveness of antiangiogenic therapy, 
namely by predicting progression-free survival and overall survival (Lassau et al., 2011). 
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Regarding antilymphangiogenic strategies, numerous compounds that could be used to 
block lymphangiogenesis already exist, although there is some delay in the translation to the 
clinic. These act mainly by targeting lymphangiogenic protein tyrosine kinases (Williams et 
al., 2010) (Table 1) or other indirect regulators of lymphangiogenic events. For instance, 
rapamycin (sirolimus), a classical immunosuppressant drug used to prevent rejection in 
organ transplantation, and a known inhibitor of the mTOR (mammalian target of 
rapamycin) signaling, has demonstrated potent antilymphangiogenic properties (Huber et 
al., 2007), and may suppress lymphatic metastasis (Kobayashi et al., 2007). mTOR is a 
member of the phosphoinositide-3-kinase-related kinase family, and is centrally involved in 
growth regulation, proliferation control and cancer cell metabolism (Rosner et al., 2008). Its 
inhibition impairs downstream signaling of VEGF-A as well as VEGF-C via mTOR to the 
ribosomal p70S6 kinase (a regulator of protein translation, and a major substrate of mTOR) 
in lymphatic endothelial cells (Huber et al., 2007). Other derivative compounds of 
rapamycin, like everolimus (RAD001) and temsirolimus (Torisel), have also demonstrated 
anti-tumor properties, namely by inhibiting tumor neovascularization (reviewed in Garcia & 
Danielpour, 2008). Recently, in patients with lymphangioleiomyomatosis (LAM, a 
progressive, cystic lung disease in women, which is associated with inappropriate activation 
of mTOR) sirolimus stabilized lung function, reduced serum VEGF-D levels, and was 
associated with a reduction in symptoms and improvement in the quality of life 
(McCormack et al., 2011).  
Inhibition of lymphangiogenesis has been shown to block lymphatic metastasis by 50-70% in 
preclinical animal models, with good safety profiles, which suggests that anti-
lymphangiogenic therapy could possibly be used safely in cancer patients, without 
disrupting normal lymphatic function (reviewed in Holopainen et al., 2011). Optimally, the 
gold-standard strategy would be the one that could inhibit both angiogenic and 
lymphangiogenic cascades, in order to compromise the success of haematogenous and 
lymphogenous dissemination. Some potential compounds are being investigated (reviewed 
in Boere et al., 2010; reviewed in Cook & Figg, 2010; reviewed in Pinto et al., 2010; reviewed 
in Stacker & Achen, 2008). 
Urothelial bladder carcinoma has experienced very few therapeutic successes, regarding 
antineovascularization therapy, in the last years. Compounds like bevacizumab (Avastin®), 
aflibercept (VEGF-Trap, AVE0005), sunitinib malate (Sutent, SU11248), sorafenib (BAY 43-
9006), vandetanib (Zactima, ZD6474) and pazopanib (Votrient, GW786034) are being tested 
in preclinical and clinical trials (reviewed in Pinto et al., 2010) (Table 2). 
Bevacizumab, as has been already referred, is a monoclonal antibody that binds and 
neutralizes VEGF in the serum. Aflibercept is a soluble fusion protein of the human 
extracellular domains of VEGFR-1 and VEGFR-2, and the Fc portion of human 
immunoglobulin G. It binds, with a higher affinity than other monoclonal antibodies, to 
VEGF and additional VEGF-family members, namely VEGF-B and placental growth factor 
(PlGF). Sunitinib is an oral multi-targeted receptor tyrosine kinase inhibitor, with activity 
against VEGF receptors and PDGF receptors, among others. Sorafenib is a small, oral 
molecule that inhibits various targets along the EGFR/MAPK (epidermal growth factor 
receptor / mitogen-activated protein kinase) signal transduction pathway, and also through 
VEGFR and PDGFR families. Vandetanib is a tyrosine kinase inhibitor, antagonist of VEGFR 
and EGFR. Pazopanib is a multitargeted tyrosine kinase inhibitor against VEGF receptors, c-
kit, and PDGF receptors (Cook & Figg, 2010). 
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Gene Role in lymphatic vessels 
Inhibitors
available
Effect of pathway inhibition 
VEGFR-2 
Receptor for the VEGF family 
of ligands. Can also 
heterodimerize with VEGFR-3.
Yes 
Secreted VEGFR-2 is a naturally 
occurring inhibitor of lymphatic 
vessel growth; however, Sorafenib† 
did not block VEGF-C/D induced 
tumor lymphangiogenesis. 
VEGFR-3 
Predominant receptor for 
VEGF-C and VEGF-D. 
Transduces survival, 
proliferation and migration 
signals. 
Yes 
Cediranib‡ blocks VEGFR-3 activity 
and inhibits lymphangiogenesis. 
Anti-VEGFR-3 antibody prevented 
tumor lymphangiogenesis with no 
effect on preexisting vessels. 
Tie1 
Not critical for lymphatic cell 
commitment during 
development, and no ligand 
has been shown. 
None 
reported. 
Tie1 knockout mouse has lymphatic 
vascular 




Receptor for Ang-1 and Ang-2. 
Appears to control vessel 
maturation. 
Yes 
Tie2-/- mice are embryonic lethal 
due to vascular defects. Inhibition 
of Ang-2 leads to tumor blood 
vessel normalization. 
EphB4 
Expressed on lymphatic 
capillary vessels. Involved in 
vascular patterning. Binds to 
the ephrinB2 ligand. 
Yes 
Mice expressing a mutant form of 
ephrinB2 lacking the PDZ binding 
domain show major lymphatic 
defects in capillary vessels and 
collecting vessel valve formation. 
FGFR3 
The ligands FGF-1 and FGF-2 
promote proliferation, 
migration, and survival of 
cultured lymphatic endothelial 
cells. FGFR3 is a direct  
transcriptional target  
of Prox1. 
Yes 
Knockdown of FGFR3 reduced 
lymphatic endothelial cells’ 
proliferation. 
IGF1R 
Both of the IGF1R ligands,  
IGF-1 and IGF-2, significantly 
stimulated proliferation  
and migration of  
primary lymphatic  
endothelial cells. 
Yes None reported. 
PDGFR 
The ligand PDGF-BB 
stimulated MAP kinase 
activity and cell motility of 
isolated lymphatic endothelial 
cells. 
Yes None reported. 
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Gene Role in lymphatic vessels 
Inhibitors
available
Effect of pathway inhibition 
MET 
The ligand for c-Met, 
hepatocyte growth factor, has 
lymphangiogenic effect, but it 
is unclear if c-Met is expressed 
on lymphatic endothelial cells.
Yes May be indirect effect. 
†Sorafenib inhibits B-Raf, PDGFRb, VEGFR-2 and c-Kit. ‡Cediranib inhibits VEGFR-1, -2, -3, PDGFRb 
and c-Kit. 
Table 1. Protein tyrosine kinases involved in lymphatic biology, and available inhibitors 
(Tie- tyrosine kinase with immunoglobulin and EGF homology domain; EphB4- ephrin 
type-B receptor 4) (reprinted by permission from © 2010 BioMed Central Ltd. Originally 
published in J. Ang. Res. 2: 1-13) 
 
Principal investigator / 
organization 
Regimen Patient population Phase 
Siefker-Radtke/MDACC 
Methotrexate + vinblastine + 






Gemcitabine + cisplatin + 
bevacizumab → cystectomy → 





Gemcitabine + cisplatin + 
bevacizumab 
First-line metastatic II 
Bajorin/MSKCC 
Gemcitabine + carboplatin + 
bevacizumab 




Gemcitabine + cisplatin ± 
bevacizumab 
First-line metastatic III 















Gemcitabine + cisplatin + 
sunitinib 
First-line metastatic II 
Hussain/University of 
Michigan 




Gallagher/MSKCC Sunitinib Second-line metastatic II 
Milowsky/MSKCC 
Gemcitabine + cisplatin + 
sorafenib 
First-line metastatic II 
Kelly/Yale 
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Principal investigator / 
organization 
Regimen Patient population Phase 
Sternberg/EORTC 
Gemcitabine + carboplatin ± 
sorafenib 
First-line metastatic II 
Dreicer/ECOG Sorafenib Second-line metastatic II 
Choueiri/DFCI Docetaxel ± vandetanib Second-line metastatic II 
Vaishampayan/Mayo 
Clinic 
Pazopanib Second-line metastatic II 
MDACC = MD Anderson Cancer Center; MUSC = Medical University of South Carolina; HOG = 
Hoosier Oncology Group; MSKCC = Memorial Sloan-Kettering Cancer Center; CALGB = Cancer and 
Leukemia Group B; EORTC = European Organization for Research and Treatment of Cancer; ECOG = 
Eastern Cooperative Oncology Group; DFCI = Dana-Farber Cancer Institute 
Table 2. Selected ongoing or recently completed trials exploring antiangiogenic therapies in 
urothelial bladder carcinoma (reprinted by permission from © 2010 Elsevier. Originally 
published in Commun. Oncol. 7: 500-504) 
4.1 Preclinical studies 
In the preclinical scenario, Videira and colleagues studied the effect of bevacizumab on 
autocrine VEGF stimulation in bladder cancer cell lines, and concluded that, at clinical 
bevacizumab concentrations, cancer cells compensate the VEGF blockade, by improving the 
expression of VEGF and related genes. This highlights the need to follow the patient’s 
adaptation response to bevacizumab treatment (Videira et al., 2011). The antiangiogenic 
treatment of tumours may restore vascular communication and, thereby, normalize flow 
distribution in tumour vasculature. The use of antiangiogenic drugs leads to improved 
tumour oxygenation and chemotherapy drug delivery (Pries et al., 2010). However, these 
mechanisms may be also the cause of malignant dissemination, because tumours elicit 
evasive resistance. Caution is recommended, due to the divergent effects that VEGF 
inhibitors can induce on primary tumor growth and metastasis (Loges et al., 2009).  
Yoon and colleagues, when exposing six human bladder cancer cell lines to an escalating 
dose of sunitinib alone or in combination with cisplatin/gemcitabine, demonstrated that 
sunitinib malate has a potent antitumor effect and may synergistically enhance the known 
antitumor effect of gemcitabine (Yoon et al, 2011).  
The first study with vandetanib in bladder cancer cell lines demonstrated its potential to 
sensitize tumor cells to cisplatin. At vandetanib concentrations of ≤2microM, the 
combination with cisplatin was synergistic, especially when given sequentially after 
cisplatin , and additive with vandetanib followed by cisplatin (Flaig et al., 2009). 
Li and colleagues studied the efficacy of pazopanib, both alone and in combination with 
docetaxel, in bladder cancer cell lines. They demonstrated that single-agent pazopanib has 
modest activity, but when given in combination with docetaxel, acted synergistically in 
docetaxel-resistant bladder cancer cells, with the potential of improved toxicity (Li et al., 2001). 
Urothelial bladder carcinoma expresses mTOR signaling molecules, providing a rationale 
for clinical trials evaluating agents targeting this pathway (Tickoo et al., 2011). In fact, some 
studies using bladder cancer cell lines have demonstrated that sirolimus and related drugs 
inhibit the growth of cancer cells and decrease their viability (Fechner et al., 2009; Hansel et 
al., 2010; Pinto-Leite et al., 2009; Schedel et al., 2011). Similar results were obtained when 
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treating bladder cancer animal models with sirolimus or everolimus (Chiong et al., 2011; 
Oliveira et al., 2011; Parada et al., 2011; Seager et al., 2009; Vasconcelos-Nóbrega et al., 2011). 
4.2 Phase II studies 
The results of a phase II trial of cisplatin, gemcitabine, and bevacizumab  (CGB) as first-line 
therapy for metastatic urothelial carcinoma revealed that CGB may improve overall survival 
― with a median follow-up of 27.2 months, overall survival time was 19.1 months. However, 
the rate of side effects was high, namely neutropenia, thrombocytopenia, anemia, and deep 
vein thrombosis/pulmonary embolism (Hahn et al., 2011).  
In a phase II trial of gemcitabine, carboplatin, and bevacizumab in patients with 
advanced/metastatic urothelial carcinoma, Balar and colleagues concluded that addition of 
bevacizumab does not improve the response rate. However, bevacizumab can be safely 
added to gemcitabine and carboplatin, because the rate of venous thromboembolisms is 
similar to the one observed with gemcitabine and carboplatin alone (Balar et al., 2011). 
Moreover, in a pooled analysis of cancer patients in randomized phase II and III studies, the 
addition of bevacizumab to chemotherapy did not statistically significantly increase the risk 
of venous thromboembolisms versus chemotherapy alone. Probably, the risk for venous 
thromboembolisms is driven predominantly by tumor and host factors (Hurwitz et al., 
2011). This type of side effect is primarily prevented by using anticoagulants simultaneously 
with cytotoxic chemotherapy (Riess et al., 2010). However, anticoagulant use during 
bevacizumab therapy may increase the risk of serious hemorrhage, although it is generally 
well tolerated (Bartolomeo et al., 2010). This controversial issue is still under scrutiny and 
more data are needed to clarify the optimal regime to reduce venous thromboembolisms in 
bladder cancer patients, particularly in those who are being treated with antiangiogenic 
drugs.   
Patients with recurrent or metastatic urothelial carcinoma who had received a prior 
platinum-containing regimen were entered in a phase II trial with aflibercept as a second-
line therapy. Aflibercept was well tolerated, but it had limited single agent activity in 
platinum-pretreated bladder cancer patients (Twardowski et al., 2009). 
In a phase II study of sunitinib in patients with metastatic urothelial cancer designed to assess 
the efficacy and tolerability of this drug in patients with advanced, previously treated 
urothelial cancer, anti-tumour responses were observed. However, sunitinib did not achieve 
the predetermined threshold of 20% activity defined by the Response Evaluation Criteria in 
Solid Tumors, and side effects such as embolic events were reported (Gallagher et al., 2010).  
In a multicenter phase II trial with sunitinib as first-line treatment in patients with 
metastatic urothelial cancer ineligible for cisplatin, on intention-to-treat analysis revealed 
that 38% of the patients showed partial responses (PRs), and 50% presented with stable 
disease (SD), the majority more than 3 months. Clinical benefit (PR + SD) was 58%. Median 
time to progression was 4.8 months and median overall survival 8.1 months (Bellmunt et al., 
2011).  
In a multicentre phase II trial of sorafenib as second-line therapy in patients with metastatic 
urothelial carcinoma, there were no objective responses to therapy. The 4-month 
progression-free survival rate was 9.5%, and the overall survival was 6.8 months (Dreicer et 
al., 2009). 
Choueiri and colleagues conducted a double-blind randomized trial in which patients with 
metastatic bladder cancer and as many as three previous chemotherapy regimens received 
intravenous docetaxel with or without vandetanib. The results demonstrated that the 
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addition of vandetanib to second-line docetaxel did not result in significant improvements 
in progression-free survival, overall survival or response rates (Choueiri et al., 2011). 
The final results of a phase II study of everolimus in metastatic urothelial cell carcinoma 
have been presented at 2011 ASCO (American Society of Clinical Oncology) Annual 
Meeting. It was demonstrated that everolimus has clinical activity in patients with advanced 
urothelial bladder cancer.  For the thirty-seven evaluable patients, the median progression-
free survival was 3.3 months, and the median overall-survival was 10.5 months. Some side 
effects possibly related to everolimus were observed, namely anemia, infection, 
hyperglycemia, lymphopenia, hypophosphatemia and fatigue (Milowsky et al., 2011). 
Dovitinib (TKI258) is an oral investigational drug that inhibits angiogenic factors, including 
FGFR and VEGFR. A multicenter, open-label phase II trial of dovitinib in advanced 
urothelial carcinoma patients with either mutated or wild-type FGFR3 is currently 
underway (Milowsky et al., 2011). 
4.3 Phase III studies 
A randomized double-blinded phase III study comparing gemcitabine, cisplatin, and 
bevacizumab to gemcitabine, cisplatin, and placebo in patients with advanced urothelial 
carcinoma is open to enrollment. The primary end point is to compare the overall survival of 
patients with advanced urothelial carcinoma treated with gemcitabine hydrochloride, 
cisplatin, and bevacizumab versus gemcitabine hydrochloride, cisplatin, and placebo. The 
secondary end points are to compare the progression-free survival, the objective response 
rate and the grade 3 and greater toxicities of these regimens in the patients (Cancer and 
Leukemia Group B, 2011). 
5. Conclusion 
Bladder cancer represents a significant health problem, and the costliest type of cancer to 
treat. Although the majority of cases present as non-muscle invasive disease, the recurrence 
and progression rates are high, which demands for long-term follow-up and repeated 
interventions. Moreover, patients with advanced tumors treated by neoadjuvant or adjuvant 
regiments frequently progress and may develop chemotherapy resistance. Therefore, 
biomarkers of tumour aggressiveness and response to therapy are urgently needed, since 
the classical formulae based on stage and grade classification are insufficient to characterize 
bladder cancer. In this sense, angiogenesis, lymphangiogenesis and lymphovascular 
invasion have been described as surrogate markers of bladder cancer progression, invasion 
and metastasis, and represent potential fields of intervention. On one hand, the combined 
analysis of these biological parameters in tumor samples with the classical 
clinicopathological parameters may improve the individual characterization of bladder 
cancer, in what concerns to its clinical and prognostic course, and should allow therapeutic 
adequacy. On the other hand, the knowledge and modulating of biological phenomena 
related with bladder cancer progression may represent a significant improvement in the 
development of new drugs and in the pathological response to therapy, which ultimately 
will lead to an increase in disease-free survival and overall survival rates. 
Targeted therapy has caused dramatic changes in the treatment of other types of tumors. 
However, in bladder cancer setting, clinical trials with molecularly targeted agents have 
been few in number and largely unsuccessful. Regarding antiangiogenic and 
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antilymphangiogenic agents, these are still considered an investigational option for 
urothelial bladder cancer patients, and more results are needed to establish their roles in the 
treatment armamentarium. Research studies with anti-neovascularization drugs should not 
only provide effective agents to treat bladder cancer patients, but also predictive biomarkers 
for response to anti-neovascularization therapy, in order to implement the concept of 
personalized therapy. 
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